The standard teaching has long been that myopia stabilizes in the late teens or early 20s. For most people, that is directionally true. But "mostly true" and "universally true" are different things — and the difference matters clinically.
Two recent bodies of work challenge the simple stabilization story: a 2024 paper by Brennan, Cheng & Bullimore in Investigative Ophthalmology & Visual Science that synthesized long-term adult refractive data, and a 2023 IMI White Paper specifically examining myopia onset and progression in adults aged 18–40. Together they provide the best available evidence on what actually happens to adult myopia over time — and the picture is more nuanced than a binary "stable/not stable" framing suggests.
The most-cited stabilization data come from the Correction of Myopia Evaluation Trial (COMET), which followed myopic children into early adulthood. COMET reported that 77% of participants had stabilized by age 18, 90% by age 21, and 96% by age 24. These numbers are widely cited as evidence that adult myopia progression is uncommon.
But COMET defined "stabilization" as less than −0.50D of change. Brennan et al. (2024, IOVS) argue that this threshold is overly liberal: a −0.49D shift over one year is counted as stable, but that amount of change accumulated over years translates to a meaningful increase in long-term myopia burden. The question is not just "did they cross a threshold?" but "how much did they shift over a lifetime?"
This does not mean myopia progresses rapidly in adulthood — annual rates are much slower than in childhood. It means that slow, continuous drift over 30 years accumulates into a clinically meaningful total shift.
The Drentse Refractive Error and Myopia (DREAM) study reported median annual refractive changes in myopes of −0.09D at ages 16–18 and −0.08D at ages 19–21. These are modest rates — but they are not zero, and they are averages with wide individual variation around them.
Foo and colleagues reported progression data from 424 myopes in the Singapore Cohort of Risk Factors for Myopia (SCORM), followed from a mean age of 14.6 to 28.6 years. The mean annualized progression rate was −0.04 ± 0.09 D/year — again modest on average, but with a standard deviation suggesting some individuals progressed substantially faster.
The IMI 2023 White Paper (Bullimore et al.) cites data from the CLAY study on soft contact lens power changes in 912 wearers aged 8–22. The mean annualized power change decreased progressively with age: −0.31 D/year for 8–13 year olds, declining to −0.10 D/year for 20–22 year olds. This is consistent with the picture of gradual deceleration rather than abrupt halt.
A large retrospective study using anonymized electronic medical records from 40 Irish optometric practices (18,620 patients, 2003–2022) found that almost three times as many adults in the youngest age group (18–24 years) experienced clinically significant myopic progression compared with the oldest age group (40–44 years) — where "clinically significant" was defined by a measurable refractive change over repeat examination visits in routine care. This European real-world dataset reinforces that young adult progression is not a rare outlier phenomenon.
The IMI 2023 White Paper reports that myopia stabilizes earlier in female patients than in male patients across four different analytical methods:
| Sex | Estimated Mean Stabilization Age | Standard Deviation |
|---|---|---|
| Female | 14.4–15.3 years | ~2 years |
| Male | 15.0–16.7 years | ~2 years |
The approximately 2-year standard deviation in both groups is important: it means the range of individual stabilization ages spans roughly 12–20 years in females and 13–21 years in males across the central ~95% of the population. Stabilization is not a moment — it is a gradual process with wide inter-individual variability.
Refraction is the conventional clinical measure, but axial length (AL) is the structural marker that directly reflects ongoing eye growth. The two are related but not interchangeable, and AL data in adults are now more available than in previous decades.
Data from the Raine Study cohort (Western Australia) found a mean axial elongation rate of approximately 0.02 mm/year between ages 20 and 28 in a community (not clinic-selected) population. This is the benchmark for "typical" adult axial growth — very slow on average, but not zero.
A large longitudinal population-based study of 9,195 Japanese adults (ages 20+, mean follow-up 3.5 years) found that 6.7% of participants had "high axial length elongation" (HALE), defined as >0.033 mm/year — the upper quartile for adults in their 20s. Key risk factors for HALE were: younger age, female sex, and pre-existing high myopia. The majority (93.3%) had lower rates of elongation, but a clinically relevant minority did not.
A long-term longitudinal study of myopic Caucasian adults corrected with phakic iris-fixated intraocular lenses found a mean annual AL increase of 0.04 ± 0.06 mm/year over a mean follow-up of approximately 12 years (144 months). Axial elongation was associated with higher baseline myopia and younger age.
In adults with very high myopia and pathologic changes, axial growth rates are higher. A large Japanese pathologic myopia cohort (1,877 patients) reported a mean annual AL growth of 0.05 ± 0.24 mm/year, with elongation rates slightly higher in women and in eyes with more advanced maculopathy.
The critical variable in all these datasets is baseline axial length and degree of myopia: higher myopia correlates with faster ongoing elongation, regardless of age.
| Population | Approximate Annual AL Growth | Source |
|---|---|---|
| Community adults, ages 20–28 (mixed myopes/emmetropes) | ~0.02 mm/year on average | Raine Study (Western Australia) |
| Community adults, ages 20+, Japanese health-check (93.3% of cohort) | <0.033 mm/year | Nishimura et al.; longitudinal, n=9,195 |
| Caucasian myopic adults, long-term follow-up | 0.04 ± 0.06 mm/year (mean ± SD) | Van der Linden et al. 2021; pIOL cohort |
| High myopia adults with pathologic changes | 0.05 ± 0.24 mm/year (mean ± SD) | Japanese pathologic myopia cohort |
| Young contact lens wearers, age 20–22 | Equivalent ~−0.10 D/year refraction change | CLAY Study (IMI 2023 citation) |
The Brennan et al. 2024 analysis puts the cumulative numbers into perspective with data from three populations:
| Baseline Myopia at Age 20 | Estimated Additional Progression by Age 50 | Data Source |
|---|---|---|
| −1.00D | Approximately −1.1D | US population prevalence modelling (Brennan et al. 2024) |
| −3.00D | Approximately −1.4D | US population prevalence modelling (Brennan et al. 2024) |
| −6.00D | Approximately −1.9D | US population prevalence modelling (Brennan et al. 2024) |
| Range across German clinical data | −1.0 to −2.9D over 20–49 years | German clinical cohort (Brennan et al. 2024) |
These are not worst-case estimates — they are central estimates from population and clinical data. The implication is that someone who enters their 20s at −4.00D may exit their 40s closer to −5.5D, even with the gradual slow progression of adult life.
The literature consistently identifies several factors associated with higher adult progression rates and greater axial elongation in adulthood. Only factors with explicit cohort support are listed here:
Importantly, the IMI 2023 White Paper is explicit that there are no large clinical trials investigating myopia control specifically in young adults aged 18–40. Evidence for treating adult progression is extrapolated from pediatric trials. This is a genuine evidence gap that the field has not yet filled.
For an evidence-literate adult myope, the key takeaways are: